



## **Mobidiag Signs Agreement with Bioportugal Química Farmacêutica Lda for the Distribution of Amplidiag® Diagnostics Tests in Portugal**

**ESPOO, Finland, September 26<sup>th</sup>, 2016** – Mobidiag Ltd, a Finnish molecular diagnostics company, today announced an agreement with Bioportugal Química Farmacêutica Lda, expert provider of products for the life science market (diagnostics, pharmaceutical, hospital furniture and equipment), for the distribution of the Amplidiag® product line. Under this agreement Bioportugal becomes the exclusive distributor of Amplidiag®, in vitro diagnostics for gastrointestinal infections, in Portugal.

“For the past months, we have been extending significantly our European distribution network. With a strong background in diagnostics, Bioportugal seemed to be the clear choice to distribute our IVD tests in Portugal. We are then very pleased to expand even more Amplidiag accessibility with the support of Bioportugal” said Tuomas Tenkanen, CEO at Mobidiag.

“Bioportugal is one of the leader companies in the molecular diagnostic in Portugal and we have been supplying several branches world recognized for the last 15 years. Modidiag portfolio of products is perfect to complete our existing list. It was a gap in our portfolio and with Mobidiag range of products we expect to cover a more extensive list of clients, increase business and have a profitable relationship for both parts” said Joaquim Teixeira, CEO at Bioportugal.

The distribution agreement is effective immediately and covers all Amplidiag® products (Amplidiag® H. pylori+ClariR, Amplidiag® Stool Parasites, Amplidiag® CarbaR+VRE, Amplidiag® C. difficile+027, Amplidiag® Bacterial GE, Amplidiag® Easy and upcoming Amplidiag® Viral GE).

### **About Amplidiag®**

Amplidiag® are innovative multiplex tests for the detection of gastrointestinal infections. They allow to screen simultaneously panels of the most relevant gastrointestinal pathogens. Based on well-established real-time PCR technology, they ensure optimal performance, suitability for high-volume screening use and cost-effectiveness in mid-sized to large laboratory settings.

**About Mobidiag Ltd.**

Established in 2000, Mobidiag develops innovative solutions to advance the diagnosis of infectious diseases and serves the European clinical diagnostics market since 2008. Mobidiag is headquartered in Espoo, Finland, with a subsidiary in Paris, France.

In addition to Amplidiag® assays, Mobidiag is able to address both high volume and on demand testing with the new Amplidiag® Easy platform, bringing the Amplidiag® suite further by automating the workflow from sample to results, and the upcoming Novodiag® platform & associated panels for a fully automated solution and suitable for smaller volumes and labs.

Visit [www.mobidiag.com](http://www.mobidiag.com) for more information.

**About Bioportugal Química Farmacêutica Lda.**

At its inception in 1990, Bioportugal was mostly involved in the fields of pharmaceuticals and diagnostics. It has now extended its portfolio to address the life science market (diagnostics, pharmaceutical, hospital furniture and equipment) thanks to a diverse team of 22 employees divided into different areas of expertise: Management, Technical Direction, Pharmacovigilance, Diagnostics (Hospital and Life Sciences), Medicines (Immunology), Technical Support, Quality, Technical Support, Administrative Services, Warehouse and Cleaning.

**Contact**

Anne Aittakorpi

+358 10 5050 770

info@mobidiag.com